InvestorsHub Logo
icon url

biomaven0

01/12/19 3:17 PM

#223128 RE: mcbio #223117

No, censoring is normal in any Kaplan-Meier curve - it just means they haven't followed the patient for long enough yet (and there has been no event with that patient).

Thus if a patient started the trial only the day before the date of the graph, they would be shown as censored after 1 day.

(Remember K-M graphs pretend everyone starts the trial at the same time).

You can read more about it here:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932959/

icon url

poorgradstudent

01/12/19 4:14 PM

#223131 RE: mcbio #223117

DCPH:

The other point I would make here is that in the 4th line dataset, the majority of the censored points are well past the median PFS for 4th line placebo (~2 months).

Doesn't absolve the dataset from a lack of reliability, but if one is fairly comfortable with the placebo response in 4th line GIST then it looks decent imo.
icon url

DewDiligence

08/13/19 11:17 AM

#225910 RE: mcbio #223117

DCPH +98% on updated phase-1 data in GIST:

https://finance.yahoo.com/news/deciphera-pharmaceuticals-reports-positive-updated-110500910.html

Competitor, BPMC is -5% on this news.